Business Description
PYC Therapeutics Ltd
ISIN : AU000000PYC7
Description
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 60.09 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -27.2 | |||||
| 3-Year EPS without NRI Growth Rate | -39.1 | |||||
| 3-Year FCF Growth Rate | -51.8 | |||||
| 3-Year Book Growth Rate | -5.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 57.96 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 10 | |||||
| 12-1 Month Momentum % | 34.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.4 | |||||
| Quick Ratio | 9.4 | |||||
| Cash Ratio | 7.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5 | |||||
| Shareholder Yield % | -9.82 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -81.92 | |||||
| ROA % | -67.3 | |||||
| ROIC % | -482.33 | |||||
| ROC (Joel Greenblatt) % | -2535.15 | |||||
| ROCE % | -80.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 11.56 | |||||
| Price-to-Tangible-Book | 8.9 | |||||
| EV-to-EBIT | -22.81 | |||||
| EV-to-EBITDA | -23.18 | |||||
| EV-to-FCF | -22.3 | |||||
| Price-to-Net-Current-Asset-Value | 8.9 | |||||
| Price-to-Net-Cash | 8.9 | |||||
| Earnings Yield (Greenblatt) % | -4.39 | |||||
| FCF Yield % | -4.17 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PYC Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 51.1 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.002071 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 34.09 | ||
| 52-Week Range (€) | 0.06662 - 0.12 | ||
| Shares Outstanding (Mil) | 3,180.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PYC Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PYC Therapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
PYC Therapeutics Ltd Frequently Asked Questions
What is PYC Therapeutics Ltd(FRA:PH7)'s stock price today?
The current price of FRA:PH7 is €0.09. The 52 week high of FRA:PH7 is €0.12 and 52 week low is €0.07.
When is next earnings date of PYC Therapeutics Ltd(FRA:PH7)?
The next earnings date of PYC Therapeutics Ltd(FRA:PH7) is .
Does PYC Therapeutics Ltd(FRA:PH7) pay dividends? If so, how much?
PYC Therapeutics Ltd(FRA:PH7) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers